Sign in Subscribe

Pasithea Reports Substantial Tumor Shrinkage With PAS-004 in Early NF1 Study, FDA Clears Phase 2

Early results show PAS-004 reduced neurofibroma size in all evaluated NF1 patients.

Pasithea Reports Substantial Tumor Shrinkage With PAS-004 in Early NF1 Study, FDA Clears Phase 2
Credit: Pasithea Therapeutics
Already have an account? Sign in.